Citigroup Maintains Buy on Neurocrine Biosciences, Raises Price Target to $242

Citigroup analyst Yigal Nochomovitz maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $204 to $242.